Plasma concentration of galantamine - influence of dose and body mass index in Alzheimer's disease (original) (raw)
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Carina Wattmo
Alzheimer's Research & Therapy, 2013
View PDFchevron_right
Galantamine plasma concentration and cognitive response in Alzheimer’s disease
Yuan-han Yang
PeerJ, 2019
View PDFchevron_right
Analyses of mortality risk in patients with dementia treated with galantamine
Shane Kavanagh
Acta Neurologica Scandinavica, 2009
View PDFchevron_right
Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial
Luc Truyen
European Journal of Neurology, 2004
View PDFchevron_right
Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen
vorapun senanarong
International Journal of Clinical Practice, 2006
View PDFchevron_right
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
Carina Wattmo
Neuropsychiatric Disease and Treatment, 2011
View PDFchevron_right
Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease
Henry Richards
Neuropsychiatric Disease and Treatment, 2014
View PDFchevron_right
Quantitative Determination of Galantamine in Human Plasma by Sensitive Liquid Chromatography--Tandem Mass Spectrometry Using Loratadine as an Internal Standard
Ramakrishna Nirogi
Journal of Chromatographic Science, 2007
View PDFchevron_right
Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients
Siwaporn Chankrachang
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2009
View PDFchevron_right
Can We Predict the Response to Galantamine in Alzheimer`s Disease Patients?
Cristina Tiu
Romanian Journal of Neurology
View PDFchevron_right
First in human study with a prodrug of galantamine: Improved benefit-risk ratio?
Geert Groeneveld
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2016
View PDFchevron_right
The Metabolism and Excretion of Galantamine in Rats, Dogs, and Humans
Nancy Van Osselaer
Drug Metabolism and Disposition, 2002
View PDFchevron_right
Galantamine: A Review Update
indu melkani
Journal of Drug Delivery and Therapeutics
View PDFchevron_right
A Review on Pharmacological Potential of Galantamine
Dr. Seema Kohli
Pharmacognosy Communications, 2020
View PDFchevron_right
Efficacy and safety of galantamine in the treatment of Alzheimer’s Disease and Alzheimer’s Disease with cerebrovascular (Mixed Dementia) (GAL-DEM-402)
Silvia Lumempouw
Medical Journal of Indonesia, 2007
View PDFchevron_right
The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease
Mark Agius
Psychiatria Danubina, 2010
View PDFchevron_right
Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease
E. Bozoglu
The American Journal of Geriatric Pharmacotherapy, 2010
View PDFchevron_right
EFFECTS OF GALANTAMINE ON ATTENTION AND MEMORY IN ALZHEIMER’S DISEASE MEASURED BY COMPUTERIZED NEU- ROPSYCHOLOGICAL TESTS Results of the Brazilian Multi-Center Galantamine Study (GAL-BRA
Márcia L. F. Chaves
2016
View PDFchevron_right
Determination of galantamine in human plasma by LC-MS/MS using carbamazepine as an internal standard: Method validation and application to a pharmacokinetic study of galantamine hydrobromide prolonged-release capsules in healthy Thai volunteers
Darunee Hongwiset
Cogent Medicine
View PDFchevron_right
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
M. Raivio
The Lancet Neurology, 2009
View PDFchevron_right
Effects of Galantamine on Attention and Memory In Alzheimer's Disease Measured by Computerized Neuropsychological Tests: Results of the Brazilian Multi- …
Francisco Vale
Arquivos de Neuro- …, 2004
View PDFchevron_right
Galantamine Pharmacological Screening and Toxicology
Krishna Sarma Pathy
View PDFchevron_right
Current status and new developments with galantamine in the treatment of Alzheimer’s disease
P. Tariot
Expert Opinion on Pharmacotherapy, 2001
View PDFchevron_right
Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01)
João Machado
Arquivos de Neuro-Psiquiatria, 2004
View PDFchevron_right
Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial
G. Bruno
Journal of Alzheimer's disease : JAD, 2011
View PDFchevron_right
Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease
Andreas U Monsch
Current Medical Research and Opinion, 2004
View PDFchevron_right
Long-term effect of galantamine on cognitive function in patients with Alzheimer's disease versus a simulated disease trajectory: an observational study in the clinical setting
Hisanori Kobayashi
Neuropsychiatric disease and treatment, 2017
View PDFchevron_right
The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia
Douglas Boggs
Clinical Neuropharmacology, 2009
View PDFchevron_right
Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study
Henry Richards
Alzheimer's Research & Therapy, 2016
View PDFchevron_right
Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients
Omar Porras
Journal of Alzheimer's disease : JAD, 2011
View PDFchevron_right